Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe dry eye disease~* Normal lid/lash anatomy, blinking function and closure as determined by the Investigator~* Literate, able to speak English, and able to complete questionnaires independently~Exclusion Criteria:~* Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the Investigator, may lead to risk of clinically significant increased bleeding~* Nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas~* Implanted metallic or electronic device in the head, a cardiac demand pacemaker, or an implanted defibrillator~* Corneal transplant in either or both eyes~* A woman who is pregnant, nursing an infant, or planning a pregnancy at the Screening Visit~* Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to the Screening Visit

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intranasal Application (Type: EXPERIMENTAL): Intranasal Tear Neurostimulator applied intranasally device (active), intranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
- Extranasal Application (Type: SHAM_COMPARATOR): Intranasal Tear Neurostimulator device applied extranasally (control) for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.

Based on this trial design, predict the completion outcome and termination type (if applicable).